



DOCKET NO: 17293DIV(HL)

RECEIVED

DEC 19 2003

TECH CENTER 1600/2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1625

Applicant: Massaro et al

) I hereby certify that this correspondence is being deposited with the United States  
Postal Service as First Class Mail in an envelope addressed to: Mail Stop  
Amendment-Non-Fee; Commissioner for Patents, P.O. Box 1450, Alexandria, VA  
22313-1450 on:

Serial No.: 09/919,195

) Date of Deposit: 12/12/2003

Conf. No. 4830

) Person making Deposit: BONNIE FERGUSON

Filed: July 31, 2001

) Signature: Bonnie Ferguson

For: METHODS AND  
COMPOSITIONS FOR THE  
TREATMENT AND PREVENTION  
OF LUNG DISEASE

) Date of Signature: 12/12/2003

Examiner: Seaman, Margaret

REPLY AND AMENDMENT

Commissioner for Patents  
Alexandria, VA 22313-1450

Dear Sir:

This Reply is being filed in reply to the Office Action mailed September 15, 2003. Applicants have the following comments.

Serial No. 09/919,195; Conf. No. 4830

Docket No. 17293DIV1 (HL)

AMENDMENTS

1-12 (Cancelled)

- 13) (Previously amended) A method for the treatment or prevention of alveolar destruction in a mammal comprising the step of administering a therapeutically effective amount of an RAR  $\beta$  antagonist having specific RAR modulating activity to said mammal, and such antagonist is not specific to at least one other RAR receptor subtype.
- 14) (Original) The method of claim 13, wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$ .
- 15) (Original) The method of claim 13 wherein said RAR $\beta$  antagonist is not specific to RAR $\gamma$ .
- 16) (Original) The method of claim 13 wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$  or RAR $\gamma$ .
- 17) (Original) The method of claim 13, wherein said composition is administered in the form of an inhalant.
- 18) (Original) The method of claim 17 wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$ .
- 19) (Original) The method of claim 17 wherein said RAR $\beta$  antagonist is not specific to RAR $\gamma$ .
- 20) (Original) The method of claim 17 wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$  or RAR $\gamma$ .
- 21) (Original) A method to increase the gas-exchange surface area of a mammalian lung in a mammal in need thereof comprising the step of administering a therapeutically effective amount of an RAR  $\beta$  antagonist having specific RAR modulating activity to said mammal.
- 22) (Original) The method of claim 21, wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$ .
- 23) (Original) The method of claim 21 wherein said RAR $\beta$  antagonist is not specific to RAR $\gamma$ .
- 24) (Original) The method of claim 21 wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$  or RAR $\gamma$ .
- 25) (Original) The method of claim 21, wherein said composition is administered in the form of an inhalant.

Serial No. 09/919,195; Conf. No. 4830

Docket No. 17293DIV1 (HL)

- 26) (Original) The method of claim 25 wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$ .
- 27) (Original) The method of claim 25 wherein said RAR $\beta$  antagonist is not specific to RAR $\gamma$ .
- 28) (Original) The method of claim 25 wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$  or RAR $\gamma$ .

29-30 (Cancelled)